Pece A, Avanza P, Galli L, Brancato R
Department of Ophthalmology and Visual Sciences, Scientific Institute H S. Raffaele, University of Milano, Italy.
Retina. 1997;17(1):12-6. doi: 10.1097/00006982-199701000-00003.
To determine if laser photocoagulation of macular choroidal neovascularization in angioid streaks may be effective in preventing severe loss of vision.
Sixty-six consecutive eyes of 52 patients with extrafoveal, well-defined choroidal neovascularization secondary to angioid streaks who underwent direct laser photocoagulation were followed for 3-108 months (mean, 34.5 months; median, 20 months).
Pretreatment mean visual acuity was 20/40 (range, 20/200-20/20), postlaser outcome was a visual acuity of 20/50 at 3 months, 20/50 at 6 months, 20/80 at 1 year, 20/80 at 2 years, 20/100 at 3 years, 20/125 at 4 years, 20/125 at 5 years, 20/100 at 6 years, and 20/80 at 7 years. During the first year after treatment there was a significant decrease in visual acuity (P < 0.01), but no significant change thereafter. Choroidal neovascularization recurred one or more times in 77% of the eyes, but by the final examination choroidal neovascularization had been eliminated completely in 31 eyes (47%). Fellow eyes with naturally progressed choroidal neovascularization were considered control eyes. Final visual acuity in treated eyes was definitely better than that in untreated eyes (P < 0.01).
This is the largest series of eyes treated by laser photocoagulation for angioid streaks and choroidal neovascularization ever reported. Laser photocoagulation of choroidal neovascularization in angioid streaks may end the choroidal neovascularization and help stabilize visual acuity or slow down visual loss. Considering the very high frequency of recurrences (77% of the eyes studied), an intense clinical and fluorangiographic follow-up period is strongly recommended, mainly for the first 3 months after treatment.
确定激光光凝治疗血管样条纹黄斑脉络膜新生血管是否能有效预防严重视力丧失。
对52例继发于血管样条纹的黄斑外、边界清晰的脉络膜新生血管患者的66只连续眼睛进行直接激光光凝,并随访3至108个月(平均34.5个月;中位数20个月)。
治疗前平均视力为20/40(范围20/200至20/20),激光治疗后3个月视力为20/50,6个月为20/50,1年为20/80,2年为20/80,3年为20/100,4年为20/125,5年为20/125,6年为20/100,7年为20/80。治疗后第一年视力有显著下降(P<0.01),但此后无显著变化。77%的眼睛脉络膜新生血管复发一次或多次,但在最后检查时,31只眼睛(47%)的脉络膜新生血管已完全消除。将自然进展的脉络膜新生血管的对侧眼视为对照眼。治疗眼的最终视力明显优于未治疗眼(P<0.01)。
这是有史以来报道的接受激光光凝治疗血管样条纹和脉络膜新生血管的最大系列病例。激光光凝血管样条纹中的脉络膜新生血管可能会终止脉络膜新生血管,并有助于稳定视力或减缓视力丧失。鉴于复发频率非常高(研究的眼睛中有77%复发),强烈建议进行密集的临床和荧光血管造影随访,主要是在治疗后的前3个月。